Symbol Lookup

Friday January 20, 2017 11:05 AM ET. Data delayed 15 minutes.
5.88
0.03 (0.43%)
Bid/Lots
5.85/22
Ask/Lots
5.90/3
Open/Prev Close
5.80/5.85
Day Range
5.80-5.90
52-Week Range
3.11-6.90
Vol/Avg Daily Vol
8.9K/95.4K
  • TSX Comp
  • TSX Venture
  • DJIA
  • S&P 500
  • NASDAQ
Price Comparison Chart
Data delayed at least 15 minutes.

Recent News»

2 New Today
Cytosorbents Launches VetResQ Blood Purification Absorber
less than 1 minute ago by MT Newswires
10:34 AM EST, 01/20/2017 (MT Newswires) -- Cytosorbents (CTSO) said Friday it has launched the VetResQ sorbent cartridge in the U.S. veterinary market. VetResQ is a blood purification absorber designed to help treat deadly inflammation and toxic...
BRIEF-Cytosorbents launches VetResQ for U.S. veterinary market
less than 1 minute ago by Thomson Reuters

Jan 20 (Reuters) - Cytosorbents Corp :

* Cytosorbents launches VetResQ for U.S. veterinary market Source text for Eikon: Further company coverage:

CytoSorbents Launches VetResQ(TM) for U.S. Veterinary Market
less than 1 minute ago by PR Newswire

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using blood purification to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces the marketing launch and commercial a...

BRIEF-Cytosorbents says U.S. Air Force determined to close study due to continued difficulty in enrolling patients in pilot study of Cytosorb product
5:14PM ET on Tuesday Jan 10, 2017 by Thomson Reuters

Jan 10 (Reuters) - Cytosorbents Corp

* Cytosorbents - Due to continued difficulty in enrolling patients in pilot study of co's Cytosorb(reg) product, c...

Cytosorbents Reports Preliminary Q4 Revenues Ahead of Street
9:37AM ET on Tuesday Jan 10, 2017 by MT Newswires
09:37 AM EST, 01/10/2017 (MT Newswires) -- Cytosorbents (CTSO) said Tuesday it expects Q4 2016 product sales of approximately $2.6 million, versus $1.5 million last year. This is ahead of the $2.5 million analyst consensus. Price: 6.15, Change: -...

Company Information

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.

CONTACT INFORMATION

Headquarters7 Deerpark Dr Ste K
MONMOUTH JUNCTION, NJ, United States 08852-1921
Phone973-329-8885
Fax732-329-8650

EXECUTIVE OFFICERS

Chairman of the BoardAl Kraus
President, Chief Executive Officer, DirectorPhillip Chan
Chief Financial OfficerKathleen Bloch
Chief Operating OfficerVincent Capponi
Chief Medical OfficerRobert Bartlett

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Stocks Ratings Sample

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

  •  
  • INK Company Insider

    Detailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®

  • S&P Capital IQ Stock Report

    S&P Capital IQ's analysts' overview and valuation, with key fundamental, quantitative, and technical analysis.

  • TDSI Morning Action Notes

    Morning Institutional Report of company updates and new recommendations.

Market Cap$149.0MBeta-0.09
Revenue (TTM)$8.2MEPS$-0.38
Shares Out.25.5MBook Value$0.32
Dividend Yield0.00%P/E--
Annual Dividend Rate0.00 USDPrice/Sales (TTM)18.2
Ex-Div Date1/1/01P/Cash Flow (TTM)--
Pay Date1/1/01Operating Margin-116.81%

*GAAP = prior to non-GAAP analyst adjusted earnings.

(Non-GAAP)*

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Stocks Calendar Sample